Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2025)

Historic Income from Continuing Operations for CollPlant Biotechnologies (CLGN) over the last 9 years, with Q3 2025 value amounting to -$3.5 million.

  • CollPlant Biotechnologies' Income from Continuing Operations rose 2278.73% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 20342.86%. This contributed to the annual value of -$16.5 million for FY2024, which is 14558.3% down from last year.
  • As of Q3 2025, CollPlant Biotechnologies' Income from Continuing Operations stood at -$3.5 million, which was up 2278.73% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, CollPlant Biotechnologies' Income from Continuing Operations peaked at $71.9 million during Q3 2021, and registered a low of -$192.6 million during Q4 2021.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$3.0 million (2021), whereas its average is -$6.4 million.
  • Examining YoY changes over the last 5 years, CollPlant Biotechnologies' Income from Continuing Operations showed a top increase of 69875.44% in 2021 and a maximum decrease of 52956.61% in 2021.
  • Over the past 5 years, CollPlant Biotechnologies' Income from Continuing Operations (Quarter) stood at -$192.6 million in 2021, then surged by 97.57% to -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then rose by 21.59% to -$4.0 million in 2024, then grew by 11.75% to -$3.5 million in 2025.
  • Its Income from Continuing Operations was -$3.5 million in Q3 2025, compared to $3.2 million in Q2 2025 and $1.6 million in Q1 2025.